Informing the pharmaceutical drug development, manufacturing and commercialization industry.
Cary, N.C. – April 26, 2017 – Industry Standard Research (ISR) has released a new report, CRO Quality Benchmarking – Phase II/III Service Providers (9th Edition), containing findings focused on service provider selection and evaluation. Kevin Olson, CEO, explains, “This report offers critical information for those involved in the outsourcing process for Phase II/III work. Many outsourcers at pharmaceutical companies find themselves selecting service providers based on incomplete information. This report provides the tools for outsourcing decision-makers to better understand the Phase II/III market and choose a provider that fits their needs.”
ISR surveyed 296 decision-makers at sponsor organizations to gather a comprehensive view of the Phase II/III service provider landscape. Respondents assess the importance of 26 selection drivers (detailed below) to paint a picture of what is most important in their service provider selection process. Then, respondents evaluate service provider performance relative to their expectations along the same dimensions. Using the selection driver data and performance ratings in tandem provides an opportunity for readers to gain a deep understanding of the Phase II/III outsourcing process and its players.
“In very much the same fashion that Consumer Reports addresses the automobile and other industries, we ask respondents to evaluate Phase II/III providers they have worked with within the past 18 months to shed light on how well provider performance stacks up against customer expectations. Mid-size providers Medpace and DCRI-Duke perform especially well compared to user expectations in Staff Characteristics attributes. In Organization Factors, only Worldwide Clinical Trials, Medpace, and Quintiles are rated as outperforming expectations across the category as a whole,” states Olson.
High performers relative to expectations in Budget Factors, Delivery Factors, and Timelines Management categories are available in the full report. In addition to service provider selection drivers and performance ratings, this report offers insights into the use of preferred providers, cost perceptions/experience, and loyalty metrics, among other areas.
For more information on ISR’s CRO Quality Benchmarking – Phase II/III Service Providers (9th Edition) report, please visit ISR’s report page.
About Industry Standard Research
Industry Standard Research is the premier, full service market research provider to the pharma and pharma services industries. With over a decade of experience, ISR delivers an unmatched level of domain expertise. For more information about ISR’s off-the-shelf intelligence and custom research offerings, please visit the company’s Web site at www.ISRreports.com, email info@ISRreports.com, or follow ISR on Twitter @ISRreports.
